Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially fatal complication in patients with chronic kidney disease (CKD), including those on dialysis [1,2]. In patients with CKD, the increased risk of thrombosis is attributed to abnormal coagulation, endothelial dysfunction, and chronic inflammation [3]. Although anticoagulation is essential for VTE patients with CKD, it remains challenging due to their high bleeding risk, particularly in the era of direct oral anticoagulants (DOACs), when treatment strategies are dependent on renal function [4].
